NASDAQ:EPRX Eupraxia Pharmaceuticals 3/20/2025 Earnings Report $4.07 +0.13 (+3.17%) Closing price 03:59 PM EasternExtended Trading$4.03 -0.04 (-0.86%) As of 04:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Eupraxia Pharmaceuticals EPS ResultsActual EPS-$0.21Consensus EPS -$0.20Beat/MissMissed by -$0.01One Year Ago EPSN/AEupraxia Pharmaceuticals Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AEupraxia Pharmaceuticals Announcement DetailsQuarterDate3/20/2025TimeAfter Market ClosesConference Call DateN/AConference Call TimeN/AUpcoming EarningsEupraxia Pharmaceuticals' next earnings date is estimated for Wednesday, August 6, 2025, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile Eupraxia Pharmaceuticals Earnings HeadlinesEupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of ShareholdersJune 2 at 6:30 PM | globenewswire.comEupraxia Pharmaceuticals to Host Virtual KOL Event to Discuss the Phase 1b/2a RESOLVE Study of EP-104GI for the Treatment of Eosinophilic Esophagitis (EoE) on May 9, 2025May 7, 2025 | financialpost.comTrump Knows Exactly What He's DoingREVEALED: $194 Trillion Trump Market Pattern Trump fires off a tweet and stocks tank… He gives a speech and the markets soar… Now, a new Trump executive order is set to set off a wave worth a potential $194 trillion in the markets. And Wall Street insider Larry Benedict says it could hand investors who missed out on Trump’s first term a second chance.June 3, 2025 | Brownstone Research (Ad)Eupraxia Pharmaceuticals to Host Virtual KOL Event to Discuss the Phase 1b/2a RESOLVE Study of EP-104GI for the Treatment of Eosinophilic Esophagitis (EoE) on May 9, 2025May 7, 2025 | globenewswire.comEupraxia Pharmaceuticals Inc.: Eupraxia Pharmaceuticals Reports First Quarter 2025 Financial ResultsMay 7, 2025 | finanznachrichten.deEupraxia Pharmaceuticals Reports First Quarter 2025 Financial ResultsMay 6, 2025 | globenewswire.comSee More Eupraxia Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Eupraxia Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Eupraxia Pharmaceuticals and other key companies, straight to your email. Email Address About Eupraxia PharmaceuticalsEupraxia Pharmaceuticals (NASDAQ:EPRX) is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company's lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee. Eupraxia Pharmaceuticals Inc. is based in VICTORIA, BC.View Eupraxia Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Ollie’s Q1 Earnings: The Good, the Bad, and What’s NextBroadcom Earnings Preview: AVGO Stock Near Record HighsUlta’s Beautiful Q1 Earnings Report Points to More Gains Aheade.l.f. Beauty Sees Record Surge After Earnings, Rhode DealCrowdStrike Stock Slips: Analyst Downgrades Before Earnings Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsAdvance Auto Parts: Did Earnings Defuse Tariff Concerns? Upcoming Earnings Broadcom (6/5/2025)Oracle (6/10/2025)Adobe (6/12/2025)Accenture (6/20/2025)FedEx (6/24/2025)Micron Technology (6/25/2025)Paychex (6/25/2025)NIKE (6/26/2025)PepsiCo (7/10/2025)Bank of America (7/14/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
